JENKEM(SH:688356)2024-06-11 08:24Group 1: Product Development - The injectable cross-linked sodium hyaluronate gel project is currently undergoing technical review, with all inspections passed so far, but the expected registration time is still uncertain [1][2] - The injectable sodium hyaluronate composite solution project has completed clinical enrollment and is currently in the follow-up stage [2] Group 2: Market Strategy - The company plans to first obtain approval for the injectable cross-linked sodium hyaluronate gel and the injectable sodium hyaluronate composite solution, with potential future development of more functional medical device product lines based on these two products [2] - The company will not establish its own sales team, and the specific sales model is still under evaluation [2] Group 3: Innovation and Competition - The company is developing a novel three-component lipid nanoparticle delivery system, which has independent intellectual property advantages [2] - The development of nucleic acid drugs related to synthetic biology is a new application scenario for the company's drug delivery platform [2] - The company focuses on early innovative projects and aims to establish long-term cooperation with clients to address homogenization competition [2] - The company plans to enrich its product line, develop new materials and delivery platforms, and explore new market directions [2] - The company actively communicates with international clients to alleviate concerns [2] Group 4: Financial Insights - The inconsistency between revenue and cash inflow in Q1 2024 is mainly related to the payment collection cycle [3]